drugset / Trial / NCT00109083

A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine

NCT00109083

Phase 2 Completed 300 enrolled SK Life Science, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate whether RWJ-333369 is a safe and effective treatment in reducing the number of migraine headaches when added to a person's usual medications for acute migraine headache relief.

Timeline

Start
2002-03
Primary completion
2006-02
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Carisbamate Small molecule 100 mg
Subject Carisbamate Small molecule 300 mg
Subject Carisbamate Small molecule 600 mg

Indications